Status:
COMPLETED
Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Liver Failure, Acute
Chronic Hepatic Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A critical issue of the clinical syndrome in liver failure is the accumulation of toxins not cleared by the failing liver. Based on this hypothesis, albumin dialysis is used to remove those substances...
Eligibility Criteria
Inclusion
- severe hepatic failure on acute liver failure or acute on chronic liver failure
- hyperbilirubinemia (total plasmatic bilirubin level above 250µmol/L)
- hepatic encephalopathy or pruritus or hepatorenal syndrome.
- waiting for liver function recovery or liver transplantation
- Signed written informed consent by patient or patient's legally appointed representative or reliable person
- affiliation to social security
Exclusion
- contraindication to extra-renal epuration
- hypersensibility to albumin or excipients
- patients for whom 2 albumin dialysis treatment cannot be considered
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2017
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT02310542
Start Date
December 1 2011
End Date
September 30 2017
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Croix Rousse - Service de réanimation chirurgicale
Lyon, France, 69317